In this issue:
Survival outcomes associated with cytoreductive nephrectomy in metastatic ccRCC
Health-related quality-of-life outcomes with lenvatinib + pembrolizumab
Biomarker-driven treatment for metastatic ccRCC
Long-term efficacy with nivolumab + ipilimumab vs sunitinib in advanced RCC
Treatment-emergent hepatic toxicity with pembrolizumab + axitinib for advanced RCC
ICI therapy for advanced non-ccRCC
Impact of dedicated renal Enhanced Recovery After Surgery programme
RAS inhibitors + ICIs for RCC
Adjuvant nivolumab + ipilimumab for localised RCC at high risk of relapse after nephrectomy
Cabozantinib + nivolumab + ipilimumab for untreated advanced RCC
Please login below to download this issue (PDF)